Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs. Their pipeline includes treatments for skin disorders, cancers, Alzheimer's, inflammatory bowel diseases, asthma, allergies, lung diseases, COVID-19, eczema and lupus.
Company Overview
Hoth Therapeutics is a clinical-stage biopharmaceutical innovator targeting unmet medical needs with a diverse pipeline of therapies, including HT-001 for skin disorders and BioLexa Platform for eczema, presenting a high-risk, high-reward investment opportunity in the biotechnology sector.
Investment Thesis
Hoth Therapeutics presents a compelling, albeit high-risk, investment opportunity for investors seeking exposure to innovative biopharmaceutical development. The company's diverse pipeline, targeting a range of unmet medical needs, offers significant potential for value creation. Key value drivers include the advancement of HT-001 through clinical trials for skin disorders and the continued development of the BioLexa Platform for eczema, which is currently in Phase I clinical trials. Success in these clinical programs could lead to significant market opportunities and partnerships. Furthermore, the company's strategic collaborations with leading universities and biotechnology companies provide access to valuable intellectual property and expertise, accelerating drug development. The company's low Beta of 0.57 suggests lower volatility compared to the overall market. However, investors must acknowledge the inherent risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles, clinical trial failures, and the need for additional capital. Upcoming clinical trial results for BioLexa Platform and HT-001 represent key catalysts that could drive significant stock appreciation.
Key Highlights
- Market capitalization of $0.01 billion indicates a small-cap company with potential for high growth but also higher risk.
- P/E ratio of -0.99 reflects the company's current lack of profitability, typical for clinical-stage biopharmaceutical companies.
- Beta of 0.57 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
- Focus on unmet medical needs across a diverse range of therapeutic areas, including dermatology, oncology, and neurology, diversifies risk.
- Strategic collaborations with leading universities and biotechnology companies provide access to valuable intellectual property and expertise.
Competitors
Strengths
- Diverse pipeline of therapeutic candidates targeting a range of diseases.
- Proprietary drug compound platform (BioLexa).
- Strategic partnerships with leading universities and biotechnology companies.
- Low Beta indicates lower volatility.
Weaknesses
- Clinical-stage company with no currently approved products and no revenue.
- Small market capitalization and limited financial resources.
- Reliance on external funding to support research and development.
- Only 2 employees.
Catalysts
- Upcoming: Phase II clinical trial results for BioLexa Platform in eczema (expected late 2026).
- Upcoming: Phase II clinical trial results for HT-001 in skin disorders (expected mid-2026).
- Ongoing: Advancement of HT-ALZ program into Phase I clinical trials (anticipated 2027).
- Ongoing: Continued strategic partnerships and licensing agreements to expand pipeline.
- Ongoing: Potential for orphan drug designations for certain therapeutic candidates.
Risks
- Potential: Clinical trial failures or delays could significantly impact the company's value.
- Potential: Regulatory hurdles and delays in obtaining marketing approvals.
- Ongoing: Competition from larger pharmaceutical companies and other biotechnology firms.
- Ongoing: Dependence on external funding to support research and development.
- Ongoing: Intellectual property challenges and patent disputes.
Growth Opportunities
- BioLexa Platform for Eczema Treatment: The BioLexa Platform, currently in Phase I clinical trials for the treatment of eczema, represents a significant growth opportunity for Hoth Therapeutics. The global eczema market is projected to reach $13.7 billion by 2030, driven by the increasing prevalence of the condition and the demand for more effective treatments. Successful completion of clinical trials and subsequent commercialization of BioLexa could generate substantial revenue for Hoth. Timeline: Phase II trials expected to commence in late 2026.
- HT-001 for Skin Disorders: HT-001, a topical formulation for treating rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy, addresses a significant unmet need in cancer treatment. The market for supportive care products in oncology is growing, driven by the increasing use of targeted therapies. Positive clinical trial results for HT-001 could lead to partnerships with pharmaceutical companies and commercialization of the product. Timeline: Phase II trials expected to commence in mid-2026.
- HT-ALZ for Alzheimer's Disease: Hoth's HT-ALZ program targets Alzheimer's disease, a large and growing market with limited treatment options. The global Alzheimer's disease market is projected to reach $12.6 billion by 2030, driven by the aging population and the increasing prevalence of the disease. Successful development of HT-ALZ could position Hoth as a leader in the Alzheimer's therapeutics market. Timeline: Preclinical studies ongoing, with Phase I trials anticipated in 2027.
- HT-KIT for Mast-Cell Derived Cancers and Anaphylaxis: The development of HT-KIT to treat mast-cell derived cancers and anaphylaxis presents a targeted growth opportunity. The market for anaphylaxis treatment is expanding due to increasing awareness and diagnosis rates. Success in this area could lead to a valuable niche product for Hoth. Timeline: Preclinical studies ongoing, with Phase I trials anticipated in 2027.
- Strategic Partnerships and Licensing Agreements: Hoth's strategy of forming strategic partnerships and licensing agreements with leading universities and biotechnology companies provides access to valuable intellectual property and expertise. These collaborations can accelerate drug development and expand the company's pipeline. Continued pursuit of strategic partnerships will be crucial for Hoth's long-term growth. Ongoing: Actively seeking collaborations to expand pipeline.
Opportunities
- Successful completion of clinical trials and regulatory approvals for lead product candidates.
- Expansion of pipeline through strategic partnerships and acquisitions.
- Growing demand for novel therapies to address unmet medical needs.
- Potential for orphan drug designations and accelerated regulatory pathways.
Threats
- Clinical trial failures and regulatory setbacks.
- Competition from larger pharmaceutical companies and other biotechnology firms.
- Difficulty in raising capital to fund research and development.
- Intellectual property challenges and patent disputes.
Competitive Advantages
- Proprietary Drug Compound Platform: The BioLexa Platform is a patented drug compound platform, providing a competitive advantage in the development of new therapies.
- Strategic Partnerships: Collaborations with leading universities and biotechnology companies provide access to valuable intellectual property and expertise.
- Diverse Pipeline: A broad pipeline of therapeutic candidates targeting a range of diseases diversifies risk and provides multiple opportunities for value creation.
About
Hoth Therapeutics, Inc., founded in 2017 and headquartered in New York City, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapies for unmet medical needs. The company's mission is to improve patient outcomes by addressing a wide range of diseases through innovative research and strategic partnerships. Hoth's diverse pipeline includes therapies targeting skin disorders, cancers, Alzheimer's disease, inflammatory bowel diseases, asthma, allergies, lung diseases, and COVID-19. Their lead product candidates include HT-001, a topical formulation for treating rash and skin disorders associated with tyrosine kinase epidermal growth factor receptor inhibitor therapy, and HT-KIT for mast-cell derived cancers and anaphylaxis. Other notable programs include HT-ALZ for Alzheimer's disease, HT-003 for inflammatory bowel diseases, acne, and psoriasis, HT-004 for asthma and allergies, HT-006 for lung diseases resulting from bacterial infections, and HT-002, a novel peptide for treating COVID-19. The company is also developing the BioLexa Platform, a proprietary, patented drug compound platform currently in Phase I clinical trials for eczema, and HT-005 for treating lupus. Hoth Therapeutics leverages strategic collaborations and licensing agreements with leading academic institutions and biotechnology companies, including the George Washington University, the University of Maryland, Isoprene Pharmaceuticals, Inc., the North Carolina State University, Chelexa BioSciences, Inc., Zylö Therapeutics, Inc., the University of Cincinnati, and Weill Cornell Medicine. These partnerships provide access to cutting-edge research and technologies, accelerating the development of its therapeutic pipeline. With a market capitalization of $0.01 billion, Hoth Therapeutics is focused on advancing its clinical programs and delivering innovative solutions to patients in need.
What They Do
- Develop therapies for skin disorders associated with cancer treatments.
- Develop treatments for mast-cell derived cancers and anaphylaxis.
- Develop therapies for Alzheimer's disease and other neuroinflammatory diseases.
- Develop treatments for inflammatory bowel diseases, acne, and psoriasis.
- Develop treatments for asthma and allergies using inhalational administration.
- Develop treatments for lung diseases resulting from bacterial infections.
- Develop a novel peptide for treating COVID-19.
- Develop treatments for lupus.
Business Model
- Develops pharmaceutical assets through in-house research and development.
- Out-licenses or partners its assets with larger pharmaceutical companies for further development and commercialization.
- Generates revenue through milestone payments, royalties on sales of licensed products, and potential direct sales of approved products.
Industry Context
Hoth Therapeutics operates within the competitive biotechnology industry, characterized by rapid innovation and high regulatory hurdles. The industry is driven by the increasing demand for novel therapies to address unmet medical needs. Hoth's focus on developing therapies for a range of diseases, including skin disorders, cancers, and Alzheimer's, positions it within several high-growth market segments. The company competes with both large pharmaceutical companies and smaller biotechnology firms, including ASBP, BCTX, CRIS, DARE and ENTO, all of whom are pursuing similar therapeutic targets. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and strategic partnerships.
Key Customers
- Pharmaceutical companies seeking to license or acquire novel drug candidates.
- Patients suffering from skin disorders, cancers, Alzheimer's disease, and other diseases targeted by Hoth's pipeline.
- Healthcare providers who prescribe Hoth's therapies to their patients.
Financials
Chart & Info
Price Chart
Hoth Therapeutics, Inc. (HOTH) stock price: $0.88 (-0.01, -1.32%)
Latest News
No recent news available for HOTH.
Technical Analysis
Rationale
AI-generated technical analysis for HOTH including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Hoth Therapeutics, Inc. (HOTH) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for HOTH.
Make a Prediction
Set your price target for Hoth Therapeutics, Inc. (HOTH), choose a timeframe, and track your prediction accuracy.
Current price: $0.88
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HOTH.
Price Targets
Wall Street price target analysis for HOTH.
Insider Flow (30d)
No insider trades in the last 30 days.
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 5/100
Gross margin data is currently unavailable for this company.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Cash position data is currently unavailable for this company.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 6/100
No significant insider buying or selling recently, which is neutral for the stock outlook.
-
Short Interest 5/100
Float and volume data unavailable for liquidity analysis.
-
Price Momentum 0/100
No bullish technical signals detected. The stock lacks upward price momentum currently.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates HOTH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Frequently Asked Questions
What does Hoth Therapeutics, Inc. do?
Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for unmet medical needs. The company's pipeline includes treatments for a range of diseases, including skin disorders, cancers, Alzheimer's disease, inflammatory bowel diseases, asthma, allergies, lung diseases, and COVID-19. Hoth's business model involves developing pharmaceutical assets through in-house research and development, out-licensing or partnering its assets with larger pharmaceutical companies, and generating revenue through milestone payments, royalties, and potential direct sales of approved products. The company is focused on advancing its clinical programs and delivering innovative solutions to patients in need.
Is HOTH stock a good buy?
HOTH stock represents a high-risk, high-reward investment opportunity. The company's diverse pipeline and strategic partnerships offer significant potential for value creation. However, investors should be aware of the inherent risks associated with clinical-stage biopharmaceutical companies, including regulatory hurdles, clinical trial failures, and the need for additional capital. The company's negative P/E ratio reflects its current lack of profitability. Positive clinical trial results for BioLexa Platform and HT-001 could drive significant stock appreciation, while negative results could lead to a substantial decline. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing in HOTH.
What are the main risks for HOTH?
The main risks for Hoth Therapeutics include clinical trial failures, regulatory setbacks, competition from larger pharmaceutical companies, dependence on external funding, and intellectual property challenges. Clinical trial failures could significantly impact the company's value and delay or halt the development of its therapeutic candidates. Regulatory hurdles and delays in obtaining marketing approvals could also negatively affect the company's prospects. Competition from larger pharmaceutical companies with greater resources could limit Hoth's market share. The company's reliance on external funding makes it vulnerable to market conditions and investor sentiment. Intellectual property challenges and patent disputes could threaten the company's competitive advantage.
Is HOTH a good stock to buy?
Whether HOTH is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.
What is the HOTH MoonshotScore?
The MoonshotScore for HOTH is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.
How often is HOTH data updated?
HOTH stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to HOTH is aggregated continuously from premium financial news sources throughout the day.
What are the growth catalysts for HOTH?
Growth catalysts for Hoth Therapeutics, Inc. (HOTH) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Hoth Therapeutics, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.
Who are HOTH's main competitors?
Hoth Therapeutics, Inc. (HOTH) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether HOTH has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.
What do analysts say about HOTH?
Wall Street analyst coverage for HOTH includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.
What is HOTH's market cap?
Market capitalization (market cap) for HOTH is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows HOTH's current market cap alongside enterprise value and other valuation metrics.
How has HOTH stock performed recently?
HOTH's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing HOTH's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.
What are the risks of investing in HOTH?
Key risk categories for HOTH include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures HOTH's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.
Are insiders buying or selling HOTH?
Insider trading activity for HOTH tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.
Is HOTH a good stock for beginners?
Hoth Therapeutics, Inc. (HOTH) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.
How risky is HOTH for first-time investors?
Every stock carries risk, including Hoth Therapeutics, Inc. (HOTH). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like HOTH.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- Investment in clinical-stage biopharmaceutical companies is highly speculative and involves significant risks.